Comparison
BPC-157 vs Coenzyme Q10
Side-by-side of BPC-157 and Coenzyme Q10. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Coenzyme Q10
CoQ10 supplement guide: 100 to 300 mg/day dosing, ubiquinol vs ubiquinone absorption, Q-SYMBIO heart failure data, statin myalgia evidence.
Effects at a glance
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Coenzyme Q10
- •Q-SYMBIO trial showed 43% reduction in major cardiovascular events at 300 mg/day in heart failure
- •Reduces statin-induced myalgia in some patients at 100-200 mg/day per Banach 2014 meta-analysis
- •Migraine prophylaxis at 300 mg/day daily; AHS lists at Level B for prevention
- •Ubiquinol absorbs 2-3x better than ubiquinone in adults over 60
- •Plasma CoQ10 falls 15-40% with chronic statin therapy
- •Small blood pressure reduction (3-5 mmHg systolic) at 100-200 mg/day
Side-by-side
| Attribute | BPC-157 | Coenzyme Q10 |
|---|---|---|
| Category | peptide | supplement |
| Also known as | Body Protection Compound-157, Pentadecapeptide BPC-157 | CoQ10, ubiquinone, ubiquinol, Q10 |
| Half-life (hr) ↗ | 4 | 34 |
| Typical dose (mg) ↗ | 0.25 | 200 |
| Dosing frequency | daily (anecdotal protocols) | 1 to 3 times daily with a fat-containing meal |
| Routes | subcutaneous, intramuscular, oral | oral |
| Onset (hr) | - | 6 |
| Peak (hr) | - | 720 |
| Molecular weight | - | 863.36 |
| Molecular formula | C62H98N16O22 | C59H90O4 |
| Mechanism | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. | Mobile electron carrier between Complex I/II and Complex III of the mitochondrial electron transport chain. Ubiquinol form acts as a lipid-soluble antioxidant in cell membranes and regenerates oxidized vitamin E. |
| Legal status | Not FDA approved; research-use-only grey market; banned by WADA (2022) | Dietary supplement (most jurisdictions); prescription cardiac medication in Japan |
| WADA status | banned | allowed |
| DEA / Rx | Not FDA approved; not scheduled; research-chemical status | Not scheduled |
| Pregnancy | Insufficient data | Limited safety data; precautionary use at standard doses |
| CAS | 137525-51-0 | 303-98-0 |
| PubChem CID | 9941957 | 5281915 |
| Wikidata | Q4835418 | Q140453 |
Safety profile
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Coenzyme Q10
Common side effects
- mild GI upset (rare)
- headache (rare)
- insomnia at very high doses
Contraindications
- active warfarin therapy without monitoring (modest interaction with INR)
Interactions
- warfarin: structural similarity to vitamin K may modestly reduce warfarin efficacy; monitor INR(moderate)
- antihypertensives: additive blood pressure-lowering at high doses(minor)
- statins: statins reduce CoQ10 synthesis; CoQ10 supplementation does not affect statin efficacy(minor)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
Which Should You Take?
Coenzyme Q10 comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
- → If your priority is cardiovascular health, pick Coenzyme Q10.
- → If your priority is healthspan extension, pick Coenzyme Q10.
Edge case: If you want to avoid research-only / gray-market sourcing, Coenzyme Q10 is the more accessible choice.
Default choice: Coenzyme Q10. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between BPC-157 and Coenzyme Q10?
BPC-157 and Coenzyme Q10 differ in category (peptide vs supplement), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, BPC-157 or Coenzyme Q10?
BPC-157 half-life is 4 hours; Coenzyme Q10 half-life is 34 hours.
Can you stack BPC-157 with Coenzyme Q10?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper